Jupiter Topco LLC Makes New Investment in Twist Bioscience Corporation $TWST

Jupiter Topco LLC bought a new position in Twist Bioscience Corporation (NASDAQ:TWST) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 50,539 shares of the company’s stock, valued at approximately $5,200,000.

A number of other institutional investors have also modified their holdings of TWST. E. Ohman J or Asset Management AB acquired a new position in Twist Bioscience in the second quarter worth about $853,000. UBS Group AG raised its stake in Twist Bioscience by 28.6% during the fourth quarter. UBS Group AG now owns 662,317 shares of the company’s stock valued at $21,009,000 after buying an additional 147,389 shares in the last quarter. Allspring Global Investments Holdings LLC bought a new position in Twist Bioscience during the 1st quarter worth approximately $22,563,000. Bank of America Corp DE lifted its holdings in Twist Bioscience by 46.3% during the 1st quarter. Bank of America Corp DE now owns 584,261 shares of the company’s stock worth $27,764,000 after buying an additional 184,907 shares during the last quarter. Finally, First Trust Advisors LP bought a new position in Twist Bioscience during the 1st quarter worth approximately $4,973,000.

Insiders Place Their Bets

In related news, CEO Emily M. Leproust sold 113,318 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $125.16, for a total value of $14,182,880.88. Following the sale, the chief executive officer directly owned 818,938 shares in the company, valued at $102,498,280.08. This trade represents a 12.16% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Paula Green sold 291 shares of Twist Bioscience stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $87.32, for a total value of $25,410.12. Following the sale, the senior vice president directly owned 120,414 shares in the company, valued at $10,514,550.48. The trade was a 0.24% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 193,099 shares of company stock valued at $24,026,581. 3.08% of the stock is owned by corporate insiders.

Twist Bioscience Trading Down 1.7%

Twist Bioscience stock opened at $139.00 on Tuesday. Twist Bioscience Corporation has a 52-week low of $23.30 and a 52-week high of $155.44. The company has a quick ratio of 2.38, a current ratio of 2.67 and a debt-to-equity ratio of 0.03. The firm has a market capitalization of $8.72 billion, a price-to-earnings ratio of -62.61 and a beta of 2.14. The firm has a 50-day moving average price of $108.03 and a two-hundred day moving average price of $74.64.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings results on Monday, August 3rd. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.05). The firm had revenue of $118.38 million during the quarter, compared to analyst estimates of $114.55 million. Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. Twist Bioscience’s revenue for the quarter was up 23.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.33 EPS. Sell-side analysts expect that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on TWST. Evercore downgraded Twist Bioscience from an “outperform” rating to an “in-line” rating and set a $102.00 price target for the company. in a report on Monday, July 6th. TD Cowen restated a “buy” rating on shares of Twist Bioscience in a research note on Monday, August 3rd. Leerink Partners set a $110.00 target price on shares of Twist Bioscience in a research note on Thursday, July 16th. UBS Group set a $89.00 target price on shares of Twist Bioscience in a research note on Monday, June 15th. Finally, Barclays raised their price target on shares of Twist Bioscience from $65.00 to $95.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 24th. Eight equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $98.30.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.